Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submissions planned in 2026 – – First dual-payload iADC from Sutro's platform entered the clinic under Astellas collaboration; patient dosing underway – – Strong balance sheet with $202.6 million in cash, cash equivalents and marketable securities as of March 31, 2026; including gross proceeds from the recent capital raise, supporting operations into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2026 and recent business highlights.

GlobeNewsWire • May 14, 2026

Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Investment Research • Apr 8, 2026

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 –

GlobeNewsWire • Mar 23, 2026

Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026

Sutro Biopharma is an early-stage ADC developer, trading at a $406m market cap after a strong 6-month rally. STRO's pipeline centers on next-generation ADCs, with lead candidate STRO-004 in Phase 1 and key data expected mid-2026. Strategic partnerships, notably with Astellas, offer milestone potential, but past alliances (Ipsen, BMY, EMD Serono) have lapsed.

Seeking Alpha • Mar 13, 2026

Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.

GlobeNewsWire • Feb 25, 2026

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research • Feb 11, 2026

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about February 11, 2026, subject to the satisfaction of customary closing conditions.

GlobeNewsWire • Feb 10, 2026

Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock?

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Investment Research • Jan 22, 2026

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript

Sutro Biopharma, Inc. ( STRO ) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation November 12, 2025 10:00 AM EST Company Participants Jane Chung - CEO & Director Jonathan Fawcett Anthony Tolcher Hans-Peter Gerber - Chief Scientific Officer Conference Call Participants Tara Bancroft - TD Cowen, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Nabeel Nissar - Jefferies LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Andres Maldonado - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Greetings.

Seeking Alpha • Nov 12, 2025